While the world searches for helpful sustainable energy solutions, one small-cap company quietly changing the lithium industry landscape in the United States. Headquartered in Calgary, Canada, Volt Lithium Corp. (TSXV: VLT.v – US, OTC: VLTLF) has become the only operational Direct Lithium Extraction (DLE) operator on the continent, with a working field unit, converting oilfield […]
March 20th Biotech Update
Are we bottoming and setting up a nice long base from which to start a bull market? Perhaps. It seems like investors are getting used to the uncertainty to an extend even if there has not been a lot that has been firmly resolved. There has not been a government shut down. RFK JR. has […]
Volt Lithium: A Lean, Swift Challenger Outpacing Giants in the Lithium Race
In the high-stakes race to secure North America’s lithium future, Volt Lithium Corp. (TSXV: VLT.v – US-OTC: VLTLF), and Standard Lithium Ltd. (SLI) represent two starkly different paths. Standard Lithium’s latest milestone, announced on March 11, 2025, celebrates the Smackover Lithium joint venture (with Equinor) completing its final Direct Lithium Extraction (DLE) derisking step at […]
March 11th Biotech Update
Another day and another big loss in the market. Not even the large cap healthcare names are holding up. I do think we are likely due for a bounce back rally but I also structurally worry about the market going forward. It was pretty highly valued to start with and now with the political uncertainty […]
Mailing List
Introduction
Overview
Founded in 2011, Chimera Research Group provides completely independent and actionable investment and trading ideas backed by comprehensive fundamental research and analysis for listed companies in the biotech and pharmaceutical sectors. Our coverage focuses on early stage companies with impending FDA decisions or clinical trial results but also includes mid-to-large cap bio-pharma companies where there exists specific catalysts. Our Trade Ideas are designed to maximize the risk reward profile. Our Research Reports outline the top up-and-coming catalysts that represent the best opportunities for traders and investors.
The biopharmaceutical sector offers significant opportunities to generate big returns yet can be risky and difficult to navigate.
Subscribe to Chimera Research Group and proceed with confidence.
